Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments

Abstract:

Objective: To compare the effectiveness and long-term side effects of adjuvant therapy for patients with cervical cancer (IB1-IIA2) with intermediate-risk factors in pathology after chemotherapy alone or concurrent radiotherapy and chemotherapy, and to evaluate the quality of life and explore the feasibility of using chemotherapy alone for cervical cancer patients. Methods: Cervical cancer patients with intermediate risk factors after surgery in the Department of Gynecological Oncology, The First Affiliated Hospital of USTC West District/Anhui Provincial Cancer Hospital from February 2016 to April 2018 were retrospectively analyzed in this study. All patients underwent standard cervical cancer surgery, and were divided into chemotherapy group and concurrent radiotherapy and chemotherapy group according to the adjuvant treatment methods after surgery. The clinical efficacy and safety of the two adjuvant treatments were discussed through the indicators of treatment effectiveness, long-term toxic side effects and quality of life of the two groups. Results: There was no significant difference in cervical cancer recurrence (χ²=0.288, P=0.591) and mortality (χ²=0.238, P=0.625) between the two groups. The 3-year progression-free survival (87.70%) and 3-year overall survival (97.60%) of the radiotherapy and chemotherapy group were lower than those of chemotherapy group (81.40% and 89.70%, respectively), without significant differences (χ²=0.787, P=0.375; χ²=1.441, P=0.230). The incidence of lymphedema in the chemotherapy group (16.70%) was lower than that of the radiotherapy and chemotherapy group (37.21%), with significant differences (χ²=4.543, P=0.033). The quality of life scores of the chemotherapy group (88.28±5.84) were higher than those of the radiotherapy and chemotherapy group (78.60±8.32), with significant differences (t=6.020, P<0.001). Conclusion: Chemotherapy alone for adjuvant treatment of patients with intermediate risk factors after radical resection of IB1-IIA2 cer-vical cancer can also achieve better clinical results, and the side effects are slightly lighter than those in the radiotherapy and chemotherapy group, which can be used as an alternative adjuvant treatment.